Cancer drugs, survival and ethics: a critical look from the inside.
作者信息
Piccart Martine, Pondé Noam
机构信息
Department of Medicine, Institut Jules Bordet, Brussels, Belgium.
BrEAST Data Center, Institut Jules Bordet, Brussels, Belgium.
出版信息
ESMO Open. 2017 Feb 10;1(6):e000149. doi: 10.1136/esmoopen-2016-000149. eCollection 2016.
Abstract
摘要
相似文献
1
Cancer drugs, survival and ethics: a critical look from the inside.癌症药物、生存与伦理：从内部进行批判性审视
ESMO Open. 2017 Feb 10;1(6):e000149. doi: 10.1136/esmoopen-2016-000149. eCollection 2016.
2
Ethics in oncology: consulting for the investment industry.肿瘤学中的伦理：为投资行业提供咨询服务。
J Clin Oncol. 2007 Feb 1;25(4):444-6. doi: 10.1200/JCO.2006.10.3036.
3
Ethics committees: an inside look at how they function.伦理委员会：深入了解其运作方式
Provider. 1986 Jul;12(7):34-5.
4
The ethics of off-label use of drugs: oncology pharmacy in Italy.药物标签外使用的伦理：意大利的肿瘤药学
J Clin Pharm Ther. 2008 Apr;33(2):95-9. doi: 10.1111/j.1365-2710.2008.00902.x.
5
Arthroscopic all-inside suture repair of medial meniscus lesion in anterior cruciate ligament--deficient knees: results of second-look arthroscopies in 39 cases.前交叉韧带损伤膝关节内侧半月板损伤的关节镜下全内置缝合修复：39例二次关节镜检查结果
Arthroscopy. 2004 Nov;20(9):936-45. doi: 10.1016/j.arthro.2004.06.038.
6
Are we professionals? A critical look at the social role of bioethicists.我们是专业人士吗？对生物伦理学家社会角色的批判性审视。
Daedalus. 1999 Fall;128(4):253-74.
7
Local research ethics committees and nursing: a critical look.地方研究伦理委员会与护理：批判性审视
Br J Nurs. 1992;1(7):349-51. doi: 10.12968/bjon.1992.1.7.349.
8
A look inside: the ANA Code of Ethics Task Force.深入了解：美国护士协会道德准则特别工作组
Imprint. 2014 Feb-Mar;61(2):31.
9
Ethical issues in the development of oncology drugs.肿瘤药物研发中的伦理问题。
Clin Adv Hematol Oncol. 2018 Oct;16(10):644-647.
10
Ethics of phase 1 oncology studies: reexamining the arguments and data.肿瘤学1期研究的伦理学：重新审视相关论据和数据。
JAMA. 2003 Aug 27;290(8):1075-82. doi: 10.1001/jama.290.8.1075.
引用本文的文献
1
PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?珀尔塞福涅：我们准备好降低HER2阳性乳腺癌辅助曲妥珠单抗的使用强度了吗？
NPJ Breast Cancer. 2019 Jan 4;5:1. doi: 10.1038/s41523-018-0098-y. eCollection 2019.
2
Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?当代针对HER2阴性转移性乳腺癌的化疗试验能否检测出总生存获益？
Cancer Manag Res. 2018 Nov 8;10:5423-5431. doi: 10.2147/CMAR.S177240. eCollection 2018.
3
Progress in adjuvant systemic therapy for breast cancer.乳腺癌辅助全身治疗的进展。
Nat Rev Clin Oncol. 2019 Jan;16(1):27-44. doi: 10.1038/s41571-018-0089-9.
4
Cancer Targeting and Drug Delivery Using Carbon-Based Quantum Dots and Nanotubes.基于碳量子点和纳米管的癌症靶向和药物传递。
Molecules. 2018 Feb 10;23(2):378. doi: 10.3390/molecules23020378.
本文引用的文献
1
Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World.癌症药物定价与报销：来自世界各地给美国的经验教训。
Oncologist. 2016 Aug;21(8):907-9. doi: 10.1634/theoncologist.2016-0106. Epub 2016 Jul 6.
2
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).一种标准化、通用且经过验证的方法，用于对预期从抗癌治疗中获得的临床获益程度进行分层：欧洲肿瘤内科学会临床获益程度量表（ESMO-MCBS）。
Ann Oncol. 2015 Aug;26(8):1547-73. doi: 10.1093/annonc/mdv249. Epub 2015 May 30.
3
Enduring and emerging challenges of informed consent.知情同意的持久和新兴挑战。
N Engl J Med. 2015 Feb 26;372(9):855-62. doi: 10.1056/NEJMra1411250.
4
The 41st David A. Karnofsky Memorial Award Lecture: Academic research worldwide--quo vadis?第41届大卫·A·卡诺夫斯基纪念奖讲座：全球学术研究——路在何方？
J Clin Oncol. 2014 Feb 1;32(4):347-54. doi: 10.1200/JCO.2013.53.2549. Epub 2013 Dec 23.
5
Why your preferred targeted drugs may become unaffordable.为什么你钟爱的靶向药物可能变得负担不起
Cancer Res. 2013 Oct 1;73(19):5849-51. doi: 10.1158/0008-5472.CAN-13-1486. Epub 2013 Sep 23.
6
Health-related quality of life and cancer clinical trials.健康相关生活质量与癌症临床试验。
Ther Adv Med Oncol. 2011 Mar;3(2):57-71. doi: 10.1177/1758834010395342.
7
High drug attrition rates--where are we going wrong?高药物淘汰率——我们哪里出错了？
Nat Rev Clin Oncol. 2011 Mar 30;8(4):189-90. doi: 10.1038/nrclinonc.2011.34.
8
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer.总生存期并非晚期实体瘤新药临床试验的现实终点：基于近期报道的结直肠癌和乳腺癌III期试验的批判性评估
J Clin Oncol. 2003 May 15;21(10):2045-7. doi: 10.1200/JCO.2003.99.089.
Zotero 插件